Opinion|Videos|December 23, 2024
Infection Prevention and Leveraging EHR for Bispecific Therapy Management
Panelists discuss insights on infection prevention protocols and electronic health record (EHR)–based toxicity management strategies for patients receiving bispecific antibody therapies in relapsed/refractory multiple myeloma (RRMM).
Advertisement
Video content above is prompted by the following
- What best practices can you share regarding preventing infection in patients receiving bispecific therapies in RRMM?
- How has your institution leveraged the electronic health record to assist with standardization and management of toxicities seen with bispecific therapies?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
Effectively Managing Immunizations in the Long-Term Care Setting
5